Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 01, 2023

Safety, Efficacy, and CSF Pharmacokinetics of Intrathecal Trastuzumab in Patients With HER2+ Cancer With Leptomeningeal Metastases



Additional Info

A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics
Neuro-oncology 2023 Mar 14;25(3)557-565, PU Kumthekar, MJ Avram, AB Lassman, NU Lin, E Lee, SA Grimm, M Schwartz, KL Bell Burdett, RV Lukas, K Dixit, I Perron, H Zhang, WJ Gradishar, EI Pentsova, S Jeyapalan, MD Groves, M Melisko, JJ Raizer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading